Cause without effect

In autoimmune disease, companies

aiming to squelch the damage induced by auto-antibodies have two options: stop auto-antibody production or stop their impact on targeted tissue. By focusing on CD16, MacroGenics Inc. has chosen the latter, attempting to sever the deleterious connection between auto-antibodies and the effect of the innate immune system...